Tryfon Zarganes-Tzitzikas
Overview
Explore the profile of Tryfon Zarganes-Tzitzikas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
487
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OBrien D, Jones H, Shi Y, Guenther F, Vendrell I, Viner R, et al.
J Proteome Res
. 2025 Jan;
24(2):479-490.
PMID: 39804742
Inhibition of the mitochondrial deubiquitinating (DUB) enzyme USP30 is neuroprotective and presents therapeutic opportunities for the treatment of idiopathic Parkinson's disease and mitophagy-related disorders. We integrated structural and quantitative proteomics...
2.
Giroud C, Szommer T, Coxon C, Monteiro O, Grimes T, Zarganes-Tzitzikas T, et al.
J Med Chem
. 2024 Oct;
67(21):18943-18956.
PMID: 39425667
The S100 protein family functions as protein-protein interaction adaptors regulated by Ca binding. Formation of various S100 complexes plays a central role in cell functions, from calcium homeostasis to cell...
3.
Mackinnon S, Zarganes-Tzitzikas T, Adams C, Brennan P, Yue W
Biochimie
. 2024 Aug;
228:71-81.
PMID: 39151880
Glycolate oxidase (HAO1) catalyses the synthesis of glyoxylate, a common metabolic intermediate that causes renal failure if accumulated. HAO1 inhibition is an emerging treatment for primary hyperoxaluria, a rare disorder...
4.
Wazynska M, Butera R, Requesens M, Plat A, Zarganes-Tzitzikas T, Neochoritis C, et al.
J Med Chem
. 2023 Jul;
66(14):9577-9591.
PMID: 37450644
In search of a potent small molecular PD-L1 inhibitor, we designed and synthesized a compound based on a 2-hydroxy-4-phenylthiophene-3-carbonitrile moiety. Ligand's performance was tested in vitro and compared side-by-side with...
5.
Schuller M, Zarganes-Tzitzikas T, Bennett J, De Cesco S, Fearon D, von Delft F, et al.
Pathogens
. 2023 Feb;
12(2).
PMID: 36839595
The worldwide public health and socioeconomic consequences caused by the COVID-19 pandemic highlight the importance of increasing preparedness for viral disease outbreaks by providing rapid disease prevention and treatment strategies....
6.
Frank N, Nugent J, Shire B, Pickford H, Rabe P, Sterling A, et al.
Nature
. 2022 Sep;
611(7937):721-726.
PMID: 36108675
Small-ring cage hydrocarbons are popular bioisosteres (molecular replacements) for commonly found para-substituted benzene rings in drug design. The utility of these cage structures derives from their superior pharmacokinetic properties compared...
7.
Iordanidou D, Kallitsakis M, Tzani M, Ioannou D, Zarganes-Tzitzikas T, Neochoritis C, et al.
Molecules
. 2022 Jul;
27(14).
PMID: 35889270
The synthesis of 3,4-dihydroquinoxalin-2-ones via the selective reduction of aromatic, multifunctional nitro precursors catalyzed by supported gold nanoparticles is reported. The reaction proceeds through the in situ formation of the...
8.
Shaabani S, Gadina L, Surmiak E, Wang Z, Zhang B, Butera R, et al.
Molecules
. 2022 Jun;
27(11).
PMID: 35684392
New biphenyl-based chimeric compounds containing pomalidomide were developed and evaluated for their activity to inhibit and degrade the programmed cell death-1/programmed cell death- ligand 1 (PD-1/PD-L1) complex. Most of the...
9.
Thomaidi M, Vagiaki L, Tripolitsiotis N, Angeli G, Zarganes-Tzitzikas T, Sidiropoulou K, et al.
ChemMedChem
. 2022 Jun;
17(15):e202200246.
PMID: 35642621
Local anesthetics occupy a prime position in clinical medicine as they temporarily relieve the pain by blocking voltage-gated sodium channels. However, limited structural diversity, problems with the efficiency of syntheses...
10.
Nizami S, Millar V, Arunasalam K, Zarganes-Tzitzikas T, Brough D, Tresadern G, et al.
Sci Rep
. 2021 Oct;
11(1):20529.
PMID: 34635690
No abstract available.